233 - Efficacy and safety results from the Phase 2 clinical trial of pritelivir versus foscarnet for treatment of acyclovir-refractory and/or resistant mucocutaneous HSV infections in immunocompromised subjects

Presenting Author(s)

• 

  Camille N. Kotton, MD, FIDSA, FAST

  Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
  Massachusetts General Hospital
  Boston, Massachusetts, United States

  Slides

Co-Author(s)

• 

  Robin K. Avery, MD

  Professor of Medicine
  Johns Hopkins
  Baltimore, Maryland, United States
• 

  Kimberly Workowski, MD

  Professor
  Department of Medicine, Emory University, Atlanta, GA, USA
  Atlanta, Georgia, United States
• 

  Princy N. Kumar, MD

  Chief, Division of Infectious Diseases
  Georgetown University Medical Center
  Washington, District of Columbia, United States
• JA

  Joerg Albrecht, MD/PhD

  Cook County Health
  Chicago, Illinois, United States
• PC

  Pranatharthi Chandrasekar, md

  professor
  wayne state university
  detroit, MI, United States
• MR

  Mayur Ramesh, MD

  Senior Staff Physician, Infectious Diseases
  Henry Ford Hospital
  Detroit, MI, United States
• AW

  Anna Wald, MD, MPH

  Professor
  University of Washington
  Seattle, WA, United States
• 

  Alexander Birkmann, PhD (he/him/his)

  Vice President Virology
  AiCuris Anti-Infective Cures AG
  Wuppertal, Nordrhein-Westfalen, Germany
• MS

  Melanie E. Sumner, MSc

  Global Program Lead
  AiCuris Anti-infective Cures AG
  Wuppertal, Nordrhein-Westfalen, Germany
• BS

  Bernadette Surujbally, MSc

  Senior Director/ Biostatistics
  AiCuris Anti-Infective Cures AG
  Bishops Stortford, England, United Kingdom
• CW

  Cynthia Wat, MBBS MRCP MFPM

  Chief Medical Officer
  Aicuris Anti-infective Cures AG
  London, England, United Kingdom
• 

  Roy F. Chemaly, MD/MPH (he/him/his)

  Gerald P Bodey, Sr Distinguished Professor of Infectious Diseases
  University of Texas MD Anderson Cancer Center
  Houston, TX, United States